CRISPR Therapeutics AG just filed a prospectus, suggesting it plans to soon issue some securities

CRISPR Therapeutics AG just came out with a new prospectus, available here. This is an SEC requirement for firms looking to issue certain types of securities. An excerpt of the prospectus is provided below:


We may issue and sell our common shares having aggregate sales proceeds of up to $350.0 million from time to time. Because there is no minimum offering amount
required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares under or fully utilize the
sales agreement with Jefferie s as a source of financing.

We currently intend to use potential proceeds from this offering to fund research and clinical development
of current or additional pipeline candidates, platform extensions, manufacturing infrastructure, working capital and general corporate purposes. Pending the use of the proceeds from this offering, we intend to invest the net proceeds in direct or
guaranteed obligations of the U.S. and Swiss governments, money market instruments, interest-bearing investment-grade securities or certificates of deposit.

believe opportunities may exist from time to time to expand our current business through acquisitions or in-licenses of complementary companies or technologies. While we have no current agreements, commitments
or understandings for any specific acquisitions or in-licenses at this time, we may use a portion of the net proceeds for these purposes.



The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever CRISPR Therapeutics AG makes a similar move, sign up!

Other recent filings from the company include the following:

CRISPR Therapeutics AG's Chief Executive Officer just cashed-in 30,000 options - June 17, 2021
CRISPR Therapeutics AG director just disposed of 10,000 shares - June 15, 2021
CRISPR Therapeutics AG director was just granted 10,000 options - June 14, 2021
Amendments to Articles of Incorporation or - June 14, 2021
Statement of changes in beneficial ownership of securities - June 14, 2021

Auto Refresh